Home » Stocks » ALVR » News

AlloVir, Inc. (ALVR)

Stock Price: $34.57 USD 0.64 (1.89%)
Updated November 25, 4:00 PM EST - Market closed
GlobeNewsWire - 3 weeks ago

CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations tha...

GlobeNewsWire - 1 month ago

Findings Demonstrate Significantly Higher Health Care Costs, Health Resource Utilization, and Worse Clinical Outcomes Among Allo-HCT Patients with Viral Infections Findings Demonstrate Signifi...

GlobeNewsWire - 2 months ago

- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients

GlobeNewsWire - 2 months ago

Appointment Expands AlloVir’s Regulatory Expertise as Company Plans to Initiate Multiple Pivotal and Proof-of-Concept Trials Appointment Expands AlloVir’s Regulatory Expertise as Company Plans...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley ...

Benzinga - 3 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Other stocks mentioned: XRX, CODI, EHTH, FFIV, IQV, QDEL
GuruFocus - 3 months ago

Stock of virus therapy biotech up more than 70% in just a few days

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the closing of its upsized initial public offeri...

Market Watch - 3 months ago

AlloVir Inc. said Thursday that its upsized initial public offering priced at $17 a share, in the middle of the expected range of $16 to $18 a share.

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of its upsized initial public offeri...

Latest From StockTwits